Background: Neuroleptic malignant syndrome is a life-threatening complication
that can occur anytime during antipsychotic treatment.
Objective: The present assessment has probed the incidence and clinical profile of neuroleptic
malignant syndrome among a sample of non-western psychiatric patients and compared
with the available data in the literature with regard to prevalence and other associated
Methods: As a retrospective, record-based evaluation, all cases with diagnosis of neuroleptic
malignant syndrome during the last sixty-two months, after ruling out other imaginable
differential diagnoses, like encephalitis, meningitis and serotonin syndrome, entered the
present investigation. Clinical diagnosis, was in essence also based on the Diagnostic and
Statistical Manual of Mental Disorders, 5th edition. The assessment of independent variables
was analyzed by ‘Compression of proportions’. Statistical significance is, defined as p
Results: Among 19814 psychiatric patients, during a sixty-two months’ period, eighteen
cases received the diagnosis of neuroleptic malignant syndrome. The most prevalent symptom
was fever, which was observed in 100% of cases. Also, there was no significant difference
between the first generation versus second-generation antipsychotics. Neuroleptic
malignant syndrome was meaningfully more prevalent among male patients suffering from
schizophrenia. Similarly, it was significantly more widespread amid 18-65 years old agegroup.
Conclusion: While no significant difference was found between first-generation as opposed
to second-generation antipsychotics, neuroleptic malignant syndrome was significantly
more prevalent among young and male patients suffering from schizophrenia.